Soleno Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Soleno Therapeutics has a total shareholder equity of $264.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $296.7M and $32.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$256.78m |
| Equity | US$264.70m |
| Total liabilities | US$32.01m |
| Total assets | US$296.71m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6XC's short term assets ($258.2M) exceed its short term liabilities ($15.0M).
Long Term Liabilities: 6XC's short term assets ($258.2M) exceed its long term liabilities ($17.0M).
Debt to Equity History and Analysis
Debt Level: 6XC is debt free.
Reducing Debt: 6XC had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6XC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 6XC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.